(VIANEWS) – SALMONES CAMANCHAC (SACAM.OL), UCB (UCB.BR), EDENRED (EDEN.PA) are the highest payout ratio stocks on this list.
We have gathered information concerning stocks with the highest payout ratio up to now. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. SALMONES CAMANCHAC (SACAM.OL)
296.23% Payout Ratio
Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. Salmones Camanchaca S.A. was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. (SNSE:SALMOCAM) operates as a subsidiary of Camanchaca S.A. (SNSE:CAMANCHACA).
Earnings Per Share
As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr-2.23.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.32%.
More news about SALMONES CAMANCHAC.
2. UCB (UCB.BR)
111.48% Payout Ratio
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.22.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 125.61. Meaning, the purchaser of the share is investing €125.61 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.67%.
Yearly Top and Bottom Value
UCB’s stock is valued at €153.25 at 17:10 EST, under its 52-week high of €160.80 and way above its 52-week low of €65.40.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.8%, now sitting on 5.45B for the twelve trailing months.
More news about UCB.
3. EDENRED (EDEN.PA)
96.49% Payout Ratio
Edenred SE provides digital platform for services and payments for companies, employees, and merchants worldwide. It offers employee benefit solutions, including Ticket Restaurant, a solution that allows employees to take time out for lunch at a partner merchant; Ticket Alimentación that allows users to pay for groceries in neighborhood stores and supermarkets; Ticket Regalo, a gift voucher; Ticket CESU, a human services solution; Ticket Plus Card, a solution that enables the purchase of staples, such as food and fuel; Ticket Welfare, which employees can use to pay for a range of services, such as access to sports facilities and solutions for their children's educational needs; Ticket Guardería for companies without on-site daycare facilities; Childcare Vouchers; Ticket EcoCheque, a solutions that encourages purchase of environmentally friendly products; Ticket Kadeos Culture and Ticket Cultura that are solutions for cultural goods and services. The company also offers mobility solutions comprising Ticket Log for light vehicle fleet management; Ticket Fleet Pro and Ticket Cargo for truck fleet management; Ticket Car for employees to pay for fuel and other business travel expenses; UTA Edenred for paying tolls, optimize routes, pay for roadside assistance and truck servicing, and for VAT reimbursement; fuel cards; and refund services for VAT and excise duties. In addition, it provides complementary solutions comprising corporate payment, invoice processing automation, and salary card solutions. Edenred SE was founded in 1962 and is headquartered in Issy-les-Moulineaux, France.
Earnings Per Share
As for profitability, EDENRED has a trailing twelve months EPS of €1.01.
PE Ratio
EDENRED has a trailing twelve months price to earnings ratio of 48.97. Meaning, the purchaser of the share is investing €48.97 for every euro of annual earnings.
Yearly Top and Bottom Value
EDENRED’s stock is valued at €49.46 at 17:10 EST, way below its 52-week high of €61.46 and way above its 52-week low of €35.72.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.6%, now sitting on 2.5B for the twelve trailing months.
Sales Growth
EDENRED’s sales growth is 17.1% for the ongoing quarter and 8.4% for the next.
More news about EDENRED.
4. NEURONES (NRO.PA)
54.19% Payout Ratio
Neurones S.A., an information technology (IT) services company, provides infrastructure, application, and consulting services in France and internationally. Its infrastructure services include infrastructure management, manages public and private cloud services, IT operations, user support, DevOps, cybersecurity, IT service management, information system governance, and automation. The company also provides application services in the areas of SAP, digital, WEB, mobility, UX/UI, enterprise content and document management, business process management, robotic process automation, dematerialization, IT consulting for finance, big data, and DevOps, IT training and change management, and Innovation connected devices (IOT). In addition, it offers consulting services, including management and digital transformation, and digital marketing consulting; digital transformation services in the areas of agile/scrum, DevOps, CI/CD, cloud, infrastructure as code, cyber security, analytics, big data, mobility, digital workplace, connected devices, innovations, client experience, UX/UI, and digital marketing, as well as internal process digitization, ECM/BPM, RPA, dematerialization, AI, predictive maintenance, machine learning, and blockchain; and managed services/outsourcing services. The company serves banking/insurance, services/consumer goods, energy/utilities/healthcare, technologies/media/telecoms, industry/public works and civil engineering, and public sector markets. Neurones S.A. was founded in 1984 and is based in Nanterre, France.
Earnings Per Share
As for profitability, NEURONES has a trailing twelve months EPS of €1.96.
PE Ratio
NEURONES has a trailing twelve months price to earnings ratio of 23.37. Meaning, the purchaser of the share is investing €23.37 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.95%.
Volume
Today’s last reported volume for NEURONES is 2114 which is 75.38% below its average volume of 8587.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 12, 2024, the estimated forward annual dividend rate is 1.2 and the estimated forward annual dividend yield is 2.94%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 741.17M for the twelve trailing months.
More news about NEURONES.
5. EUROPRIS (EPR.OL)
47.25% Payout Ratio
Europris ASA operates as a discount variety retailer in Norway. It sells own brand and branded merchandise, including laundry and cleaning, pet food and accessories, storage, confectionery and snacks, candles, seasonal items, garden, and home and interior categories, as well as groceries, toys, and do it yourself (DIY) products The company also offers its products through online shopping. Europris ASA was founded in 1992 and is headquartered in Fredrikstad, Norway.
Earnings Per Share
As for profitability, EUROPRIS has a trailing twelve months EPS of kr5.53.
PE Ratio
EUROPRIS has a trailing twelve months price to earnings ratio of 11.86. Meaning, the purchaser of the share is investing kr11.86 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.76%.
More news about EUROPRIS.
6. TECHNIP ENERGIES (TE.PA)
31.71% Payout Ratio
Technip Energies N.V., together with its subsidiaries, operates as an engineering and technology company for the energy transition in Europe, Russia, the Asia Pacific, Africa, the Middle East, and the Americas. The company operates in two segments, Projects Delivery; and Technology, and Products and Services. It is involved in the engineering, procurement, construction management, commissioning, and transport and installation of various energy projects. The company also engages in the study, engineering, procurement, construction, and project management of various onshore and offshore facilities related to gas monetization, ethylene, hydrogen, refining, and chemical processing from biofuels and hydrocarbons. In addition, it develops, designs, commercializes, and integrates a range of technologies in gas monetization, refining, petrochemicals and fertilizers, hydrogen, and sustainable chemistry; provides land and marine-based loading and transfer systems services to the oil and gas, petrochemical, chemical, and decarbonization industries; and offers a range of project management consulting services to the energy industry. Further, the company offers robotics, visual intelligence, and surveillance solutions, as well NDT services; operations and maintenance consulting. Additionally, it provides Capture.Now, a set of decarbonization solutions; Canopy, an integrated suite of post-combustion carbon capture solutions; heat transfer technologies and products; INO15, a floating offshore wind solutions; SnapLNG, an electrified low-carbon LNG solution, as well as advisory and digital services. Technip Energies N.V. was incorporated in 2019 and is headquartered in Nanterre, France.
Earnings Per Share
As for profitability, TECHNIP ENERGIES has a trailing twelve months EPS of €1.64.
PE Ratio
TECHNIP ENERGIES has a trailing twelve months price to earnings ratio of 14.27. Meaning, the purchaser of the share is investing €14.27 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.33%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 100% and 17.4%, respectively.
More news about TECHNIP ENERGIES.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
More news about 1.
